{"schema_version":"secwatch.filing_event.v1","accession":"0001479290-24-000034","form_type":"8-K","ticker":null,"cik":"0001479290","company_name":"Revance Therapeutics, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.293412+00:00","generated_at":"2026-06-05T08:37:49.177102+00:00","sec_items":["1.01","2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Revance Q4 product revenue $58.5M (+28%); guides 2024 at least $280M","bullets":["Q4 product revenue $58.5M (DAXXIFY $24M, RHA $34.5M); full year product $212.7M (+80% YoY).","2024 product revenue guidance at least $280M; DAXXIFY cervical dystonia launch mid-year.","GAAP net loss FY 2023 $324M; Adjusted EBITDA loss $160.1M; cash $253.9M as of Dec 31.","President Dustin Sjuts steps down effective March 31; separation includes 18 months base salary.","OPUL payments business exit by Q1 2024, generating ~$20M annual savings."],"urls":{"canonical":"https://secwatch.observer/filing/0001479290-24-000034","json":"https://secwatch.observer/filing/0001479290-24-000034.json","markdown":"https://secwatch.observer/filing/0001479290-24-000034.md","text":"https://secwatch.observer/filing/0001479290-24-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000034/0001479290-24-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000034/rvnc-20240223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:37:49.177102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3432c3c69b8415131b7450f4885d508ad1fa0a9e","claim":"Revance Therapeutics, Inc. updated its 2024 guidance (initiated).","evidence_excerpt":"2024 product revenue guidance of at least $280 million, supporting blockbuster potential in U.S. aesthetics.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000034/0001479290-24-000034-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2024"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"e85bb5b8720f4fed6ed9f7266bcac3f87d9b14bf","claim":"Revance Therapeutics, Inc. updated its the fourth quarter and full year ended December 31, 2023 guidance (initiated).","evidence_excerpt":"On February 28, 2024, the Company issued a press release announcing its financial results for the three months and fiscal year ended December 31, 2023 and the Company's financial outlook for 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000034/0001479290-24-000034-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"56c2c44b5c","claim":"Dustin Sjuts departed as President at Revance Therapeutics, Inc..","evidence_excerpt":"On January 8, 2024, the Company announced that Mr. Sjuts is stepping down from his current position as President of the Company, effective as of March 31, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000034/0001479290-24-000034-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepping down"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"cd2956bf1a8b530227a887d8e7f3c6fcb2656433","claim":"Revance Therapeutics, Inc. amended Amendment No. 2 to the Technology Transfer, Validation and Commercial Fill/Finish Services Agreement with Ajinomoto Althea, Inc. dba Ajinmoto Bio-Pharma Services (effective 2024-02-26).","evidence_excerpt":"On February 26, 2024, Revance Therapeutics, Inc. (the “Company”) and Ajinomoto Althea, Inc. dba Ajinmoto Bio-Pharma Services, a contract development and manufacturing organization (“ABPS”), entered into Amendment No. 2 to the Technology Transfer, Validation and Commercial Fill/Finish Services Agreement (the “Amendment”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929024000034/0001479290-24-000034-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Ajinomoto Althea, Inc. dba Ajinmoto Bio-Pharma Services"},{"label":"Effective","value":"2024-02-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}